Showing results (1-10 of 134) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2026
Beyond amplification: precision approaches to targeting HER2Maxwell R Lloyd, Mark D Pegram, Seth A WanderClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2021
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic OpportunitiesMaxwell R Lloyd, Laura M Spring, Aditya Bardia, et al.JCO Oncology Practice|July 7, 2026
SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast CancerMaxwell R Lloyd, Rebecca A Shatsky, Neil Love, et al.Nature Reviews. Clinical Oncology|August 23, 2024
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell R Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging roleMaxwell R Lloyd, Seth A Wander, Erika Hamilton, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 20, 2025
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast CancerJimmitti Teysir, Maxwell R Lloyd, Samer Alkassis, et al.Hematology/Oncology Clinics of North America|August 7, 2013
Treating the HER2 pathway in early and advanced breast cancerMark D PegramClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2024
Cracking the Genomic Code of CDK4/6 Inhibitor ResistanceSeth A Wander, Aditya BardiaNEJM Evidence|May 30, 2024
CDK4/6 Inhibitor Efficacy in <i>ESR1</i>-Mutant Metastatic Breast CancerMaxwell R Lloyd, Jamie O Brett, Ariel Carmeli, et al.Seminars in Oncology|July 26, 2002
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factorMark D Pegram, David M ReesePageof 14